$0.58
0.03%
Nasdaq, Jan 02, 10:05 pm CET
ISIN
US92941V1008
Symbol
VYNE

VYNE Therapeutics Inc Stock price

$0.58
+0.22 62.12% 1M
-0.93 61.60% 6M
-0.00 0.03% YTD
-2.75 82.59% 1Y
-2.12 78.52% 3Y
-116.06 99.50% 5Y
-2,066.54 99.97% 10Y
-2,066.54 99.97% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.00 0.03%
ISIN
US92941V1008
Symbol
VYNE
Industry

Key metrics

Basic
Market capitalization
$19.3m
Enterprise Value
$-50.0k
Net debt
positive
Cash
$19.4m
Shares outstanding
31.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
37.1 | 63.1
EV/Sales
negative | negative
EV/FCF
0.0
P/B
0.6
Financial Health
Equity Ratio
77.9%
Return on Equity
-76.5%
ROCE
-117.0%
ROIC
-259.7%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$520.0k | $306.0k
EBITDA
$-37.5m | $-44.9m
EBIT
$-37.5m | $-36.5m
Net Income
$-33.7m | $-25.6m
Free Cash Flow
$-38.4m
Growth (TTM | estimate)
Revenue
6.1% | -38.8%
EBITDA
- | -2.9%
EBIT
-0.9% | 16.4%
Net Income
0.6% | 35.7%
Free Cash Flow
-27.3%
Margin (TTM | estimate)
Gross
-
EBITDA
-7,159.0% | -14,666.7%
EBIT
-7,162.4%
Net
-6,421.0% | -8,366.1%
Free Cash Flow
-7,320.6%
More
EPS
$-0.8
FCF per Share
$-1.2
Short interest
1.5%
Employees
13
Rev per Employee
$40.0k
Show more

Is VYNE Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

VYNE Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a VYNE Therapeutics Inc forecast:

7x Buy
70%
3x Hold
30%

Analyst Opinions

10 Analysts have issued a VYNE Therapeutics Inc forecast:

Buy
70%
Hold
30%

Financial data from VYNE Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
0.52 0.52
6% 6%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 12 12
15% 15%
2,285%
- Research and Development Expense 26 26
7% 7%
4,990%
-38 -38
-
-7,213%
- Depreciation and Amortization 0.02 0.02
-
4%
EBIT (Operating Income) EBIT -38 -38
1% 1%
-7,218%
Net Profit -34 -34
1% 1%
-6,471%

In millions USD.

Don't miss a Thing! We will send you all news about VYNE Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

VYNE Therapeutics Inc Stock News

Neutral
PRNewsWire
17 days ago
MILWAUKEE , Dec. 18, 2025 /PRNewswire/ -- The Ademi Firm is investigating VYNE (Nasdaq: VYNE) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Yarrow Bioscience. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.
Neutral
Seeking Alpha
19 days ago
VYNE Therapeutics Inc. (VYNE) Yarrow Bioscience, Inc. - M&A Call Prepared Remarks Transcript
Neutral
Business Wire
19 days ago
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of VYNE Therapeutics Inc. (NASDAQ: VYNE) and Yarrow Bioscience, Inc. is fair to VYNE shareholders. Upon completion of the proposed transaction, VYNE shareholders are expected to own approximately 3% of the combined company. Halper Sadeh encourages VYNE shareholders to click here to lear...
More VYNE Therapeutics Inc News

Company Profile

VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercialize solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company is headquartered in Bridgewater, NJ.

Head office United States
CEO David Domzalski
Employees 13
Founded 2011
Website vynetherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today